

- II. Claims 7, 8, 10, and 11, drawn to cell-based assay with SSeCKS gene promoter linked to reporter gene, classified in class 435, subclass 6;
- III. Claim 9, drawn to cell-based assay with cyclin D gene promoter linked to reporter gene, classified in class 435, subclass 6;
- IV. Claim 12, drawn to cell based assay measuring cyclin D transport, classified in class 435, subclass 4;
- V. Claims 13-15, drawn to method of inhibiting cell proliferation using nucleic acid encoding SSeCKS, classified in class 514, subclass 44;
- VI. Claims 16-17, drawn to method for determining SSeCKS protein level in cancer, classified in class 435, subclass 7.23;
- VII. Claim 18, drawn to method for determining SSeCKS nucleic acid level in cancer, classified in class 435, subclass 6;
- VIII. Claim 19, drawn to treatment with compound that prevents nuclear transport of cyclin D, e.g. SSeCKS fusion polypeptide, classified in class 514, subclass 2; and
- IX. Claim 20, drawn to treatment with a compound that increases expression of SSeCKS, classified in class 514, subclass indeterminate, no compounds disclosed.

In support of the present restriction requirement, the Examiner has alleged that the subject matter of the pending claims represents nine distinct inventions.

The requirement for restriction is respectfully traversed because there is clearly a structural and functional relationship between the method claims of Group V and VIII. For example, the claims of Groups V and VIII relate to methods for inhibiting cell proliferation based on inhibition of cyclin D activity. Given the relationship between the subject matter encompassed by the pending claims of Groups V and VIII, Applicants assert that there would not be an undue search burden to examine the pending claims as a single group.

However, in order to be fully responsive to the requirement for restriction, Applicants elect, with traverse, the claimed method of inhibiting cell proliferation encompassed by the subject matter of Group V, *i.e.*, Claims 13-15 encompassing methods of inhibiting cell

proliferation. Withdrawal of the requirement for restriction and favorable consideration and allowance is earnestly solicited.



Respectfully submitted,

RECEIVED

DEC 06 2002

TECH CENTER 1600/2900

Carmella L. Stephens

Lisa B. Kole

PTO Reg. No. 35,225

Carmella L. Stephens

PTO Registration No. 41,328

ATTORNEYS FOR APPLICANTS

(212) 408-2539

BAKER BOTTS, L.L.P.

30 Rockefeller Plaza

New York NY 10112

Encls.